CymaBay Therapeutics announces initiation of its next phase 2 study of seladelpar
CymaBay announced initiation of a new Phase 2 study of seladelpar in patients with primary biliary cholangitis. The primary endpoint will be the change in alkaline phosphatase , a parameter that has been used in prior clinical studies with PBC and is believed to reflect the diseas statuse. December 07, 2016